mushroom_icon.png

This covers our next venture, EI.ventures, will combine psychoactive compounds such as DEA-registered psilocybin, together with AI and blockchain technology, to empower customized compounds and personalized formulas to better mental wellness.


Science - Beyond the fluff 🔍

There is a rapidly increasing inventory of research papers and abstracts regarding the synthesis the Psilocybin and its analogues or homologues.  Advances in the areas of traditional organic chemistry synthesis, bio synthesis and enzymatic synthesis processes are driving this research.

The primary goal of these efforts are to lower the cost of synthesizing psilocybin and other relevant psycho active compounds in order to more broadly study the efficacy of treatment of proposed treatments. Very much similar as advances made in synthesizing antibiotics this century for wider and cost effective distribution. As well as recent advances in the manipulation of yeast and RNA production of THC and CBD products.

The results of this work is being openly published or is easily available via such as National Institute of Mental Health databases in the Untied states and world wide through similar organizations. The rapidly increasing knowledge base regarding the brain chemistry of mental health and wellness are fueling these efforts world wide.

What we are doing 🍄

We continue to identify and align with licensed chemists and labs In the traditional fields of organic and bio chemistry as well as (so called) kitchen chemists who have been innovating underground processes for years.

Primary goal being to quicken and bring to market so called “1 pot” synthesis of relevant psychoactive materials or compounds. So named “1 pot” synthesis involves combining the fundamental components in simple combinations, adding bio active yeasts, enzymes, bio neutral solvents and allowing the targeted materials to better self organize which require less refinement to purge toxic lab solvents usually used in traditional synthetic lab processes.

We are working to integrate an innovative blend of traditional organic and bio chemistry with new fields of electro and sono chemistry and various non traditional or leading edge extraction and compounding processes to create a cost effective production of psychoactive compounds. The processes manipulates and modifies the ingredients at the molecular level enhancing their bonding efficacy, bio-availability as well as hydrophilic qualities.


Key Psilocybin figures and statistics

  • Across the globe, an estimated 300 million people have depression and around 60 million people suffer from bipolar disorder.

  • In 2018, researchers from Johns Hopkins University recommended that psilocybin be legalized for medical use.

  • Oregon and California all have potential ballot initiatives in process to legalize psilocybin for medical use. Denver recently passed decriminalization of psilocybin in May 2019 while Oregon looks to have its vote in 2020.

  • In late 2018, the FDA upgraded psilocybin to "breakthrough therapy" status, meaning the FDA acknowledged its potential and vowed to expedite its review process.

3df9a73a-c157-42e6-aa87-b9e812ff99b1.jpg

Our world today faces a Mental Health crisis of staggering proportions. In America, over 40 million people are dealing with mental health concerns. What’s more, 6 out of 10 young people have depression and do not receive any mental health treatment.

Across the globe, an estimated 300 million people have depression and around 60 million people suffer from bipolar disorder.

A report issued in 2018 by The Lancet Commission states that mental health disorders could cost the global economy up to $16 trillion by the year 2030 if the problems are not addressed.

Orthogonal Thinker plans to pioneer this new category of supplements, herbal remedies and plant medicines over the next 10 years. What’s more, we plan to be on the leading edge of research via our relationships with Academic and Scientific Institutions, along with our own research lab.

e226903c-bc54-4473-8edd-be78ae4ade20.gif

As far out as this may all sound... the legalization of medical psilocybin is closer than some might consider.

Oregon, Denver and California all have potential ballot initiatives in process. Denver could vote on the decriminalization of psilocybin in May 2019 while Oregon looks to have its vote in 2020.

If any or all of these initiatives pass, the momentum will shift in a big way. I believe it will happen in a shorter timeframe than it took to legalize Medical Marijuana.

What gets me excited is the growing number of studies which suggest psilocybin can truly help turn the mental health crisis around.

Psilocybin therapy, which combines the use of psilocybin with psychological support, has been studied since the 1950s. Research from this past decade is even more promising.

Micro-dosing with Psilocybin has been shown to help cancer patients with depression and anxiety. It helps relieve symptoms for people who experience cluster headaches.

3b7c35bd-5809-443f-a04f-8aca4cefd3c3.gif

It can be used to treat addiction, and it could be an alternative to typical depression treatments. Psilocybin could also help people overcome drug, alcohol, and nicotine addictions.

The National Institute of Mental Health estimates that 9% of the U.S. population suffers from personality disorders including depression, schizophrenia, bipolar disorder and others. This needs to change.

EI (Emotional Intelligence) is a Farma based company looking at natural plant and fungi based solutions for humans emotional regression or stagnation manifested as mental illness or lack of creative process.

Our Goals

  1. Formulate and synthesize a pro drug of Psilocybin for higher efficacy and less side effects for the treatments of depression mild to drug resistances.

  2. Formulate and synthesize a Psilocybin based compound to aid in mental thought and intellectual expansions for well individuals. 

  3. Use evidence based medicine approaches with in IRB (institutional review boards) for studying and refining therapies.

  4. Maintain federal legality with Schedule 1 Drug license for manufacturing and study applications while streamlining efficient and timely end user use through none FDA drug licensing development of State Legal avenues.  i.e. legal state cannabis. 

Our Solutions

  • Form a team of leading medical and business oriented researchers for process implementation of evidence based medical principles.

  • Form, partner or purchase an entity with a lab offer schedule 1 DEA  access to psilocybin and its chemical derivatives. 

  • This business arrangement should be in a states poised for legal state legislation now pending in Colorado and California.

  • Form or employ a lobbyist network for facilitation of legality and work ability of business model.

  • Work with IRB’s for validation of study protocols for legitimate medical use and well and safety and efficacy.

  • Supply end users first through a dispensary model and grow partnerships with medical community for use of products with acute emotional issue in an out-patient and inpatient setting.

Our Outline

  • Acquire initial funding $1M for establishment of Medical and Board of Advisors teams.

  • Schedule I license acquisition.

  • Finish multi IRB study submissions.

  • Identify lab partner or purchase for manufacturing and study.

  • Funding round 2 $3-5M. 

  • Synthesize and refine compounds and uses at the lab through research protocols with IRB’s qualified studies.

  • Finish Patent process.

  • Funding round 3  $5+M

  • First implementation with dispensary model and training of guides and center of excellence for first use

  • Partnership with freestanding hospital and urgent cares for implementations and interventions of urgency Round 4 $25M